Response and acquired resistance to everolimus in anaplastic thyroid cancer
about
Translational Bioinformatics: Past, Present, and FutureToward rapamycin analog (rapalog)-based precision cancer therapyAmino acid management in cancerTargeting cancer with kinase inhibitorsClinical tumor sequencing: opportunities and challenges for precision cancer medicineCIViC databaseGenomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.Management of anaplastic thyroid cancerThe phosphoinositide 3-kinase pathway and therapy resistance in cancerBeyond indigestion: emerging roles for lysosome-based signaling in human diseaseAutophagy in thyroid cancer: present knowledge and future perspectivesDifferential network analysis from cross-platform gene expression data.Moonshots and metastatic disease: the need for a multi-faceted approach when studying atypical responses.Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimusPrecision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.The current use and attitudes towards tumor genome sequencing in breast cancer.Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in GlioblastomaEverolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutationCarfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancerPrecision medicine for advanced prostate cancer.A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast CancerSecreted IGFBP5 mediates mTORC1-dependent feedback inhibition of IGF-1 signalling.Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group studyEverolimus induces Met inactivation by disrupting the FKBP12/Met complexBRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cellsGenomic Profiling of Thyroid Nodules: Current Role for ThyroSeq Next-Generation Sequencing on Clinical Decision-Making
P2860
Q26766146-1A31C39F-20BF-4A0F-98E0-67C8242E78DAQ26795606-8561FB27-2576-4D7B-8110-608070F85DD7Q26798087-91EDFE8E-70BA-4BBA-AF8F-67B7F5363F42Q26865765-D6599CA3-43F6-4ED9-B840-5BD938A29579Q27027942-72573596-1443-4735-AE6B-A82CDD47C0E2Q27612411-DED586B9-4015-4F67-8B95-E55E0E9C1931Q27853189-F1E13C68-47A8-4077-B8EF-8BC850BA5ABEQ28080836-C459D9DD-0206-40CC-B23C-2CF554A05BD4Q28082811-E47721F3-5721-478F-ABDF-E4385CC8299CQ28084027-E9BECAF4-ECA1-49B3-A904-C568923BEA64Q28086785-F8C8D77D-58EB-4273-AEAA-2A74D146556CQ31133441-AD4D61E4-6D24-439D-9FBF-05E2B3012B5DQ33767521-0CF2D126-7F0D-42E6-83D5-EF54FB2923D2Q33823065-2E919E35-A4E5-4216-9271-99C64423C0E4Q34995919-6B63211A-8957-46CA-A6D7-C0FA287E2FF8Q35234108-3B14BFF3-9FB4-4F40-8806-EAFE654047B0Q35623044-939C9ACD-16D6-4DF3-BCE3-17D929BE160FQ35872419-0201D8D8-C800-4B48-BC44-EC1D89E648CCQ36064946-4C282C8C-A421-49BD-8D6B-5BC9107A72A4Q36173629-42C2CC9A-4512-40B1-85A7-A563D23BC242Q36288987-80FC157A-4300-4CDF-842E-18F020AB83B0Q36316627-9DB49E9A-BC5B-4177-BA0E-91700530A1F4Q36316643-4EED37D3-F1DD-4C0A-9E4A-F63E4CC6E038Q36380974-D92A0E5C-9337-4FE4-B557-FF532D5E7B89Q36618604-263ABFA5-B334-4CC6-B2ED-5F31E77E2012Q36638214-DFBBA4EE-D927-4C64-A70A-9A40CF3E5371Q36796606-0B73D75C-5DE3-44B0-8E61-E394760307B9Q36932702-C6E78048-8908-4DA7-AD58-283F9491A452Q36963020-7AFBDF02-4B73-4F35-9DB8-0BA5752D3B74Q36992455-BED8C13A-56EC-4A57-B5C9-037B8D3876B7Q37027094-BBD307EF-9DC1-4EE8-A33C-A590E167D57AQ37086070-6BC2C740-0CE7-44FE-AFC8-DCB4289CF720Q37114034-C5C9585B-ABC8-4624-957E-D82479B74485Q37146398-33EA267C-9202-4BB1-97E6-45F009F203F6Q37210786-C66D54F6-2B50-4813-A1A0-41BF08DE72E8Q37217474-9DFF184C-4424-49E0-A45A-C6E979AE304EQ37429034-0EDAE371-21EC-4991-A357-525283929D9BQ37457794-1A5B5B61-A6C7-4DA1-B8D0-26EC8883E809Q37565246-3DAFABA8-318C-423F-806A-804F4E3F8A92Q37616591-90ABB505-23B6-43EC-A1E9-9E155C3F5982
P2860
Response and acquired resistance to everolimus in anaplastic thyroid cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Response and acquired resistance to everolimus in anaplastic thyroid cancer
@ast
Response and acquired resistance to everolimus in anaplastic thyroid cancer
@en
Response and acquired resistance to everolimus in anaplastic thyroid cancer.
@nl
type
label
Response and acquired resistance to everolimus in anaplastic thyroid cancer
@ast
Response and acquired resistance to everolimus in anaplastic thyroid cancer
@en
Response and acquired resistance to everolimus in anaplastic thyroid cancer.
@nl
altLabel
Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
@en
prefLabel
Response and acquired resistance to everolimus in anaplastic thyroid cancer
@ast
Response and acquired resistance to everolimus in anaplastic thyroid cancer
@en
Response and acquired resistance to everolimus in anaplastic thyroid cancer.
@nl
P2093
P2860
P50
P3181
P356
P1476
Response and acquired resistance to everolimus in anaplastic thyroid cancer
@en
P2093
Brian C Grabiner
Daniel T Ruan
David J Kwiatkowski
David M Sabatini
Eliezer M Van Allen
Glenn J Hanna
Jochen H Lorch
Justine A Barletta
Nathanael Gray
Nikhil Wagle
P2860
P304
P3181
P356
10.1056/NEJMOA1403352
P407
P577
2014-10-09T00:00:00Z